SciELO - Scientific Electronic Library Online

 
vol.27 número1Factores asociados a la presentación víscero-hemolítica de loxoscelismo en el Hospital Nacional Cayetano Heredia, entre el 2000 y 2008Trasplante de epiplón para el nervio ciático lesionado índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Acta Médica Peruana

versión On-line ISSN 1728-5917

Resumen

PEREZ GALDOS, Proel. Direct Medical Costs of Epilepsy in Hospital III Miguel Grau of EsSalud (Peruvian Social Security). Acta méd. peruana [online]. 2010, vol.27, n.1, pp.37-42. ISSN 1728-5917.

Objectives: To determine direct costs of epilepsy in a population assigned to one hospital in Peruvian Social Security (EsSalud) during year 2006. To point out which group of epileptic patients generate more direct costs. Methodology: A retrospective study including 462 epilepsy patients was performed in order to estimate medical direct costs, considering the Sales Value = Retail price - 19% (Peruvian added value tax), obtained from the EsSalud rate lists; as well as prices for antiepileptic drugs (AED) (generics), which are the lowest within Peru. Descriptive and analytic statistics were used, as well as Chi square and Student’s t tests.   Results: Fifty three per cent patients were male, and their average age was 40.7 years (± 22.03 SD); 95.7% of epileptic episodes were generalized crises, 17.7% were refractory, the average number of hospital visits was 6.26 (± 3.16 SD), 9.1% patients were hospitalized, and the average hospital stay was 6.93 days (± 4.72 SD). Annual direct costs were 71,433.24 US Dollars, average direct costs for controlled epilepsy were USD 118.5 and for refractory epilepsy, the amount was 321.9 USD (p<0.0001).   Conclusion: Costs for specialized consultations (37%) and AEDs (34%) represented the greatest annual expenses, and the direct average cost was 154.61 USD/patient/year. Average costs for refractory epilepsy were three times higher than those for controlled epilepsy; and direct costs reported in this study are quite lower than those reported in industrialized countries and even in neighboring countries.

Palabras clave : Costs and cost analysis; epilepsy; epileptic.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons